Evidence map›Paper›PMID 32300019›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption.

Viviane M Andrade, Carla Mavian, Dunja Babic, Thaissa Cordeiro, Mark Sharkey, Labelle Barrios, Christian Brander, Javier Martinez-Picado, Judith Dalmau, Anuska Llano and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Review
  3. Mouse Models of HIV-Associated Atherosclerosis.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Viviane M AndradeMolecular Cell and Developmental Biology, Miller School of Medicine, University of Miami, Miami, FL 33136.ORCID 0000-0002-5056-298X
Carla MavianEmerging Pathogens Institute, University of Florida, Gainesville, FL 32610.ORCID 0000-0003-3819-5520
Dunja BabicDepartment of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136.
Thaissa CordeiroDepartment of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136.
Mark SharkeyDepartment of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136.
Labelle BarriosDepartment of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136.ORCID 0000-0003-4033-6054
Christian BranderInstitut de Recerca de la Sida, 08916 Badalona, Spain.
Javier Martinez-PicadoInstitut de Recerca de la Sida, 08916 Badalona, Spain.ORCID 0000-0002-4916-2129
Judith DalmauInstitut de Recerca de la Sida, 08916 Badalona, Spain.ORCID 0000-0001-7513-3711
Anuska LlanoInstitut de Recerca de la Sida, 08916 Badalona, Spain.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.ORCID 0000-0001-9914-9662
Jeffrey JacobsonLewis Katz School of Medicine, Temple University, Philadelphia, PA 19122.
Christy L LavineBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Michael S SeamanBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Marco SalemiEmerging Pathogens Institute, University of Florida, Gainesville, FL 32610.
Mario StevensonDepartment of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136; MStevenson@med.miami.edu.
University of Miami · USRed de Investigación en Sida · ESBeth Israel Deaconess Medical Center · USUniversity of Florida · USBrigham and Women's Hospital · USTemple University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Rana Chakraborty · 2007 to 2026
$33.8M
UC Davis Biostatistics CoreP01AI131568 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI STEVENSON, MARIO · 2017 to 2021
$7.1M
Viral evolution in peropheral macrophages and brain during progression to AIDSR01NS063897 · NINDS · UNIVERSITY OF FLORIDA · PI SALEMI, MARCO · 2009 to 2021
$7.0M
Revealing HIV-1 persistence in myeloid cell reservoirsR01MH116701 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Mario Stevenson · 2018 to 2026
$4.0M
NIAID NIH HHS P01 AI131568NIAID NIH HHS P30 AI073961NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIMH NIH HHS R01 MH116701NINDS NIH HHS R01 NS063897
6 · The paper itself

Abstract

HIV-1 persists in cellular reservoirs that can reignite viremia if antiretroviral therapy (ART) is interrupted. Therefore, insight into the nature of those reservoirs may be revealed from the composition of recrudescing viremia following treatment cessation. A minor population of macrophage-tropic (M-tropic) viruses was identified in a library of recombinant viruses constructed with individual envelope genes that were obtained from plasma of six individuals undergoing analytic treatment interruption (ATI). M-tropic viruses could also be enriched from post-ATI plasma using macrophage-specific (CD14) but not CD4+ T cell-specific (CD3) antibodies, suggesting that M-tropic viruses had a macrophage origin. Molecular clock analysis indicated that the establishment of M-tropic HIV-1 variants predated ATI. Collectively, these data suggest that macrophages are a viral reservoir in HIV-1-infected individuals on effective ART and that M-tropic variants can appear in rebounding viremia when treatment is interrupted. These findings have implications for the design of curative strategies for HIV-1.

Indexed as

Anti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveBiological ClocksCD4-Positive T-LymphocytesHIV-1HIV InfectionsHIV SeropositivityHumansMacrophagesProvirusesViral LoadViremiaAnti-Retroviral Agentsanalytical treatment interruptionHIV-1 reservoirsmacrophages

Identifiers

PMID32300019
PMCPMC7211992
OpenAlexW3017015334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.